Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YKST02 in Primary IgA Nephropathy
NCT07498673Phase 1Recruiting
- Start
- May 2026
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YKST02 in IgA nephropathy (IgAN). Primary endpoints: Incidence of Adverse Events and Serious Adverse Events at 25 weeks, Change from Baseline in Urine Protein-to-Creatinine Ratio at 25 weeks and 2 more. Started May 2026; status: recruiting.
02
Drugs
YKST02
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07498673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07498673.